



FDA-approved small-molecule kinase inhibitors

Wu, Peng; Nielsen, Thomas E.; Clausen, Mads Hartvig

Published in:
Trends in Pharmacological Sciences

Link to article, DOI:
[10.1016/j.tips.2015.04.005](https://doi.org/10.1016/j.tips.2015.04.005)

Publication date:
2015

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015). FDA-approved small-molecule kinase inhibitors. *Trends in Pharmacological Sciences*, 36(7), 422-439. <https://doi.org/10.1016/j.tips.2015.04.005>


General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.


- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal


If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.







(A)




(B)








(A)




Dasatinib

(B)




(C)




Bosutinib

(D)




(A)




Ruxolitinib

(B)



(C)



(D)

